KalVista Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 79 to 82.
Hone Your Stock-Picking Skills By Focusing On These Factors
This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes.
Over 100 years of market history shows that the top-performing stocks often have an RS Rating north of 80 as they begin their biggest price moves.
KalVista Pharmaceuticals is now considered extended and out of buy range after clearing an 11.45 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 0% EPS growth in its most recent report. Revenue rose 0%. The next quarterly results are expected on or around Sep. 4.
The company earns the No. 242 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
